BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. J Natl Cancer Inst 2017;109. [PMID: 29370427 DOI: 10.1093/jnci/djx089] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 34.7] [Reference Citation Analysis]
Number Citing Articles
1 Riccardo F, Barutello G, Petito A, Tarone L, Conti L, Arigoni M, Musiu C, Izzo S, Volante M, Longo DL, Merighi IF, Papotti M, Cavallo F, Quaglino E. Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas ​. Vaccines (Basel) 2020;8:E166. [PMID: 32268572 DOI: 10.3390/vaccines8020166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JE. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clin Cancer Res 2019;25:5852-8. [PMID: 31243121 DOI: 10.1158/1078-0432.CCR-19-0899] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 12.3] [Reference Citation Analysis]
3 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
4 Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Chiang CL, Choi HC, Lam KO, Chan BY, Lee SF, Yeung SY, Lau KS, Chan SY, Choy TS, Yuen KK. Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer. Asia Pac J Clin Oncol 2019;15 Suppl 2:5-13. [PMID: 30887726 DOI: 10.1111/ajco.13114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Ann Oncol 2018;29:1800-6. [PMID: 29860358 DOI: 10.1093/annonc/mdy197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
7 Lee Y, Lee S, Sung JS, Chung HJ, Lim AR, Kim JW, Choi YJ, Park KH, Kim YH. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Res Treat 2021;53:123-30. [PMID: 32810930 DOI: 10.4143/crt.2020.559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yamashiro Y, Kurihara T, Hayashi T, Suehara Y, Yao T, Kato S, Saito T. NTRK fusion in Japanese colorectal adenocarcinomas. Sci Rep 2021;11:5635. [PMID: 33707574 DOI: 10.1038/s41598-021-85075-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Esmati E, Rezaei S, Jafari F. A case of multiple primary malignancies including peritoneal mesothelioma surviving over 11 years. Clin Case Rep 2021;9:e04096. [PMID: 34026139 DOI: 10.1002/ccr3.4096] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2020;33:38-46. [PMID: 31375766 DOI: 10.1038/s41379-019-0324-7] [Cited by in Crossref: 129] [Cited by in F6Publishing: 124] [Article Influence: 43.0] [Reference Citation Analysis]
11 He X, Jiao XD, Liu K, Qin BD, Wu Y, Ling Y, Liu J, Xu AQ, Song K, Zang YS. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report. JCO Precis Oncol 2021;5:PO. [PMID: 34036227 DOI: 10.1200/PO.20.00534] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Seet AOL, Tan AC, Tan TJ, Ng MCH, Tai DWM, Lam JYC, Tan GS, Gogna A, Too CW, Tan BS, Takano A, Lim A, Lim TH, Lim ST, Dent RA, Ang MK, Yap YS, Tan IBH, Choo SP, Toh CK, Lim EH, Farid M, Skanderup AJ, Iyer NG, Lim WT, Tan EH, Lim TKH, Tan DSW. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience. JCO Precis Oncol 2021;5:PO. [PMID: 34250396 DOI: 10.1200/PO.20.00261] [Reference Citation Analysis]
13 Jin Z, Sinicrope FA. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:300. [PMID: 33467526 DOI: 10.3390/cancers13020300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 Procaccio L, Bergamo F, Daniel F, Rasola C, Munari G, Biason P, Crucitta S, Barsotti G, Zanella G, Angerilli V, Magro C, Paccagnella S, Di Antonio V, Loupakis F, Danesi R, Zagonel V, Del Re M, Lonardi S, Fassan M. A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers (Basel) 2021;13:5128. [PMID: 34680277 DOI: 10.3390/cancers13205128] [Reference Citation Analysis]
15 Lim KHT, Kong HL, Chang KTE, Tan DSW, Tan IBH, Mohamad F, Soh SY, Pang BN, Soo RA, Choo SP, Hsieh WS, Aung L. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force. Asia Pac J Clin Oncol 2021. [PMID: 34806337 DOI: 10.1111/ajco.13727] [Reference Citation Analysis]
16 Antoniotti C, Ongaro E, Falcone A, Cremolini C. The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. Int J Mol Sci 2018;19:E2298. [PMID: 30081606 DOI: 10.3390/ijms19082298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Dienstmann R, Salazar R, Tabernero J. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book 2018;38:231-8. [PMID: 30231342 DOI: 10.1200/EDBK_200929] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
18 Lee SJ, Hong JY, Kim K, Kim KM, Kang SY, Lee T, Kim ST, Park SH, Park YS, Lim HY, Kang WK, Lee J, Park JO. Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. J Oncol 2020;2020:4659062. [PMID: 32411236 DOI: 10.1155/2020/4659062] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Wang J, Li R, Li J, Yi Y, Liu X, Chen J, Zhang H, Lu J, Li C, Wu H, Liang Z. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing. J Transl Med 2021;19:433. [PMID: 34657620 DOI: 10.1186/s12967-021-03108-6] [Reference Citation Analysis]
20 Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AAL, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris V. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol 2019;3:PO. [PMID: 33015522 DOI: 10.1200/PO.19.00141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
21 Dos Santos W, Sobanski T, de Carvalho AC, Evangelista AF, Matsushita M, Berardinelli GN, de Oliveira MA, Reis RM, Guimarães DP. Mutation profiling of cancer drivers in Brazilian colorectal cancer. Sci Rep 2019;9:13687. [PMID: 31548566 DOI: 10.1038/s41598-019-49611-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
22 Cusumano VT, Myint A, Corona E, Yang L, Bocek J, Lopez AG, Huang MZ, Raja N, Dermenchyan A, Roh L, Han M, Croymans D, May FP. Patient Navigation After Positive Fecal Immunochemical Test Results Increases Diagnostic Colonoscopy and Highlights Multilevel Barriers to Follow-Up. Dig Dis Sci 2021. [PMID: 33609211 DOI: 10.1007/s10620-021-06866-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fu Y, Li Z, Gao F, Yang J, Wu H, Zhang B, Pu X, Fan X. MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas. Front Oncol 2021;11:669197. [PMID: 33996597 DOI: 10.3389/fonc.2021.669197] [Reference Citation Analysis]
24 Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano F, Zeppa P, Garbossa D, Pellerino A, Rudà R, Soffietti R, Fagioli F, Papotti M, Cassoni P, Bertero L. NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. Int J Mol Sci 2020;21:E753. [PMID: 31979374 DOI: 10.3390/ijms21030753] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
25 Russo A, Incorvaia L, Malapelle U, Del Re M, Capoluongo E, Vincenzi B, Chiari R, Cortesi L, Danesi R, Florena AM, Fontanini G, Gori S, Marchetti A, Normanno N, Pinto C, Sangiolo D, Silvestris N, Tagliaferri P, Tallini G, Cinieri S, Beretta G. The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. Crit Rev Oncol Hematol 2021;:103436. [PMID: 34371157 DOI: 10.1016/j.critrevonc.2021.103436] [Reference Citation Analysis]
26 Guo Y, Guo XL, Wang S, Chen X, Shi J, Wang J, Wang K, Klempner SJ, Wang W, Xiao M. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. Oncologist 2020;25:e1671-80. [PMID: 32627883 DOI: 10.1634/theoncologist.2020-0356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol 2019;30:viii16-22. [PMID: 31738428 DOI: 10.1093/annonc/mdz384] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 30.5] [Reference Citation Analysis]
28 Zhuang Y, Wang H, Jiang D, Li Y, Feng L, Tian C, Pu M, Wang X, Zhang J, Hu Y, Liu P. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer 2021;21:380. [PMID: 33836681 DOI: 10.1186/s12885-021-08108-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Eefsen RL, Simonsen KS, Grundtvig P, Klarskov L, Chen IM, Høgdall D, Jensen BV, Lorentzen T, Poulsen TS, Theile S, Nielsen D, Høgdall E. Genomic landscape of treatment refractory metastatic colorectal cancer. Acta Oncol 2021;:1-8. [PMID: 34606390 DOI: 10.1080/0284186X.2021.1984575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Fernández-Montes A, Grávalos C, Pericay C, Safont MJ, Benavides M, Élez E, García-Alfonso P, García-Paredes B, Carrato A, Aranda E. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. Clin Colorectal Cancer 2020;19:165-77. [PMID: 32507561 DOI: 10.1016/j.clcc.2020.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Filippi R, Depetris I, Satolli MA. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion. Expert Opin Pharmacother 2021;22:677-84. [PMID: 33576301 DOI: 10.1080/14656566.2021.1876664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G, Tabernero J, Elez E. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Ther Adv Med Oncol 2020;12:1758835920936089. [PMID: 32782486 DOI: 10.1177/1758835920936089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol 2018;29:1394-401. [PMID: 29538669 DOI: 10.1093/annonc/mdy090] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
34 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
35 Kim JH, Hong JH, Choi YL, Lee JA, Seo MK, Lee MS, An SB, Sung MJ, Cho NY, Kim SS, Shin YK, Kim S, Kang GH. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. J Pathol 2021. [PMID: 34402529 DOI: 10.1002/path.5779] [Reference Citation Analysis]
36 Anandappa G, Cunningham D. Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer. JAMA Oncol 2019;5:1262-4. [PMID: 31268483 DOI: 10.1001/jamaoncol.2019.1447] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Xu Z, Peng X, Kong Y, Cui Y, Li Y, Guo Y. The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis. Cancer Treat Res Commun 2021;29:100455. [PMID: 34619647 DOI: 10.1016/j.ctarc.2021.100455] [Reference Citation Analysis]
38 Kourie HR, Eid R, Haddad FG. Agnostic biomarkers in gastrointestinal tumors: microsatellite instability and NTRK. Per Med 2021;18:5-7. [PMID: 33124525 DOI: 10.2217/pme-2020-0036] [Reference Citation Analysis]
39 Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. Int J Mol Sci 2019;20:E5319. [PMID: 31731495 DOI: 10.3390/ijms20215319] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
40 Lau DK, Burge M, Roy A, Chau I, Haller DG, Shapiro JD, Peeters M, Pavlakis N, Karapetis CS, Tebbutt NC, Segelov E, Price TJ. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Rev Anticancer Ther 2020;20:251-70. [PMID: 32186929 DOI: 10.1080/14737140.2020.1744439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Pfarr N, Kirchner M, Lehmann U, Leichsenring J, Merkelbach‐bruse S, Glade J, Hummel M, Stögbauer F, Lehmann A, Trautmann M, Kumbrink J, Jung A, Dietmaier W, Endris V, Kazdal D, Evert M, Horst D, Kreipe H, Kirchner T, Wardelmann E, Lassen U, Büttner R, Weichert W, Dietel M, Schirmacher P, Stenzinger A. Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays. Genes Chromosomes Cancer 2019;59:178-88. [DOI: 10.1002/gcc.22819] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
42 Abi-Raad R, Prasad ML, Adeniran AJ, Cai G. Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology. Cancer Cytopathol 2020;128:803-11. [PMID: 32931153 DOI: 10.1002/cncy.22353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ruiz-Bañobre J, Kandimalla R, Goel A. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. JCO Precis Oncol 2019;3:PO. [PMID: 32914007 DOI: 10.1200/PO.18.00260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Solomon JP, Hechtman JF. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res 2019;79:3163-8. [PMID: 31196931 DOI: 10.1158/0008-5472.CAN-19-0372] [Cited by in Crossref: 64] [Cited by in F6Publishing: 20] [Article Influence: 21.3] [Reference Citation Analysis]
45 Shinozaki-Ushiku A, Ishikawa S, Komura D, Seto Y, Aburatani H, Ushiku T. The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion. Gastric Cancer 2020;23:944-7. [PMID: 32189226 DOI: 10.1007/s10120-020-01061-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lin A, Zhang H, Hu X, Chen X, Wu G, Luo P, Zhang J. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. Pharmacol Res. 2020;159:105028. [PMID: 32569820 DOI: 10.1016/j.phrs.2020.105028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
47 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
48 Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther 2019;12:3171-9. [PMID: 31118670 DOI: 10.2147/OTT.S177051] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
49 Ma SC, Zhu HB, Wang J, Zhang YP, Guo XJ, Long LL, Guo ZQ, Wu DH, Dong ZY, Bai X. De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. Front Oncol 2021;11:666145. [PMID: 34221982 DOI: 10.3389/fonc.2021.666145] [Reference Citation Analysis]
50 Ambrosini M, Fucà G, Duca M, Damian S, De Santis F, Corti F, Cresta S, de Braud F, Di Nicola M. Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy? Crit Rev Oncol Hematol 2021;169:103532. [PMID: 34800655 DOI: 10.1016/j.critrevonc.2021.103532] [Reference Citation Analysis]
51 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S, Futreal PA, Wu H, Liang Z. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol 2019;32:1053-64. [PMID: 30723297 DOI: 10.1038/s41379-019-0212-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
53 García-Alfonso P, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, Ramón Y Cajal S, Hernández-Losa J, Landolfi S, Musulén E, Cuatrecasas M, Navarro S. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2020;22:1976-91. [PMID: 32418154 DOI: 10.1007/s12094-020-02357-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Chou A, Fraser T, Ahadi M, Fuchs T, Sioson L, Clarkson A, Sheen A, Singh N, Corless CL, Gill AJ. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas—a study of 4569 cases. Mod Pathol 2020;33:924-32. [DOI: 10.1038/s41379-019-0417-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
55 Williams SR, Juratli TA, Castro BA, Lazaro TT, Gill CM, Nayyar N, Strickland MR, Babinski M, Johnstone SE, Frosch MP, Silverman IM, Ely HA, Kaplan AB, D'Andrea MR, Bihun IV, Hoang K, Batchelor E, Christiansen J, Cahill DP, Barker FG 2nd, Brastianos PK. Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas. J Neurol Surg B Skull Base 2019;80:562-7. [PMID: 31750041 DOI: 10.1055/s-0038-1676821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
56 Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 2019;30:1417-27. [PMID: 31268127 DOI: 10.1093/annonc/mdz204] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 51.5] [Reference Citation Analysis]
57 Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A, Kowalski PE, Zhong Y, Johnson M, Li C, Ramani AK, Siddaway R, Nobre LF, de Antonellis P, Dunham C, Cheng S, Boué DR, Finlay JL, Coven SL, de Prada I, Perez-Somarriba M, Faria CC, Grotzer MA, Rushing E, Sumerauer D, Zamecnik J, Krskova L, Garcia Ariza M, Cruz O, Morales La Madrid A, Solano P, Terashima K, Nakano Y, Ichimura K, Nagane M, Sakamoto H, Gil-da-Costa MJ, Silva R, Johnston DL, Michaud J, Wilson B, van Landeghem FKH, Oviedo A, McNeely PD, Crooks B, Fried I, Zhukova N, Hansford JR, Nageswararao A, Garzia L, Shago M, Brudno M, Irwin MS, Bartels U, Ramaswamy V, Bouffet E, Taylor MD, Tabori U, Hawkins C. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10:4343. [PMID: 31554817 DOI: 10.1038/s41467-019-12187-5] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 20.7] [Reference Citation Analysis]
58 Picco G, Chen ED, Alonso LG, Behan FM, Gonçalves E, Bignell G, Matchan A, Fu B, Banerjee R, Anderson E, Butler A, Benes CH, McDermott U, Dow D, Iorio F, Stronach E, Yang F, Yusa K, Saez-Rodriguez J, Garnett MJ. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nat Commun 2019;10:2198. [PMID: 31097696 DOI: 10.1038/s41467-019-09940-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
59 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
60 Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol 2017;28:3009-14. [PMID: 29045518 DOI: 10.1093/annonc/mdx546] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
61 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
62 Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res 2018;24:1881-90. [PMID: 29363525 DOI: 10.1158/1078-0432.CCR-17-3103] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 7.8] [Reference Citation Analysis]
63 Aasebø KØ, Dragomir A, Sundström M, Mezheyeuski A, Edqvist PH, Eide GE, Ponten F, Pfeiffer P, Glimelius B, Sorbye H. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Med 2019;8:3623-35. [PMID: 31070306 DOI: 10.1002/cam4.2205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
64 Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs 2019;79:1375-94. [PMID: 31347092 DOI: 10.1007/s40265-019-01165-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
65 Pollack M, Keating K, Wissinger E, Jackson L, Sarnes E, Cuffel B. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. Curr Med Res Opin 2021;37:59-70. [PMID: 33148054 DOI: 10.1080/03007995.2020.1847057] [Reference Citation Analysis]
66 Muller C, Yurgelun M, Kupfer SS. Precision Treatment and Prevention of Colorectal Cancer-Hope or Hype? Gastroenterology 2020;158:441-6. [PMID: 31622623 DOI: 10.1053/j.gastro.2019.09.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ouali K, Pellat A, Cohen R, Svrcek M, Penault-Llorca F, André T. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Bull Cancer 2020;107:447-57. [PMID: 32067719 DOI: 10.1016/j.bulcan.2019.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Siozopoulou V, Smits E, De Winne K, Marcq E, Pauwels P. NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics (Basel) 2021;11:478. [PMID: 33803146 DOI: 10.3390/diagnostics11030478] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
69 Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, Segelov E. Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. Cancer Manag Res 2020;12:5819-30. [PMID: 32765085 DOI: 10.2147/CMAR.S213236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
70 Navarro S, Cuatrecasas M, Hernández-Losa J, Landolfi S, Musulén E, Ramón Y Cajal S, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, García-Alfonso P. [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology]. Rev Esp Patol 2021;54:41-54. [PMID: 33455693 DOI: 10.1016/j.patol.2020.07.004] [Reference Citation Analysis]
71 Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers (Basel) 2021;13:4506. [PMID: 34572729 DOI: 10.3390/cancers13184506] [Reference Citation Analysis]
72 Lasota J, Chłopek M, Wasąg B, Kowalik A, Christiansen J, Lamoureux J, Kuźniacka A, Felisiak-Gołąbek A, Liu Y, Reyes TAR, Saha R, Agaimy A, Behenska K, Biernat W, Cattaneo L, Centonze G, Daum O, Daumova M, Domagała P, Dziuba I, Geppert CE, Góźdź S, Nasierowska-Guttmejer A, Hałoń A, Hartmann A, Inaguma S, Iżycka-Świeszewska E, Kaczorowski M, Kołos M, Kopczyński J, Michal M, Milione M, Okoń K, Pęksa R, Pyzlak M, Ryś J, Waloszczyk P, Wejman J, Miettinen M. Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature. Am J Surg Pathol 2020;44:1224-34. [PMID: 32804454 DOI: 10.1097/PAS.0000000000001512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Chen S, Wang B, Fu X, Liang Y, Chai X, Ye Z, Li R, He Y, Kong G, Lian J, Li X, Chen T, Zhang X, Qiu X, Tang X, Zhou K, Lin B, Zeng J. ALKAL1 gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway. J Cancer 2021;12:150-62. [PMID: 33391411 DOI: 10.7150/jca.46447] [Reference Citation Analysis]
74 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
75 Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. J Clin Oncol 2019;37:3099-110. [PMID: 31539295 DOI: 10.1200/JCO.19.01254] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
76 Zheng CL, Lu Q, Zhang N, Jing PY, Zhang JP, Wang WP, Li GZ. Comprehensive Analysis of the Immune and Prognostic Implication of MMP14 in Lung Cancer. Dis Markers 2021;2021:5917506. [PMID: 34868395 DOI: 10.1155/2021/5917506] [Reference Citation Analysis]
77 Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 2020;5:e000634. [PMID: 32188714 DOI: 10.1136/esmoopen-2019-000634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
78 Petrelli F, Perego G, Ghidini A, Ghidini M, Borgonovo K, Scolari C, Nozza R, Rampulla V, Costanzo A, Varricchio A, Rausa E, Pietrantonio F, Zaniboni A. A systematic review of salvage therapies in refractory metastatic colorectal cancer. Int J Colorectal Dis 2020;35:783-94. [DOI: 10.1007/s00384-020-03571-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Hsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Sci Rep 2021;11:15370. [PMID: 34321583 DOI: 10.1038/s41598-021-94968-x] [Reference Citation Analysis]
80 Guler I, Askan G, Klostergaard J, Sahin IH. Precision medicine for metastatic colorectal cancer: an evolving era. Expert Rev Gastroenterol Hepatol. 2019;13:919-931. [PMID: 31475851 DOI: 10.1080/17474124.2019.1663174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
81 Roda D, Roselló S, Cervantes A. Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. Ann Oncol 2019;30:1409-10. [PMID: 31350557 DOI: 10.1093/annonc/mdz229] [Reference Citation Analysis]
82 Filip S, Vymetalkova V, Petera J, Vodickova L, Kubecek O, John S, Cecka F, Krupova M, Manethova M, Cervena K, Vodicka P. Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. Int J Mol Sci 2020;21:E5255. [PMID: 32722130 DOI: 10.3390/ijms21155255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
83 Matsuoka T, Yashiro M. Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World J Gastrointest Oncol 2020; 12(1): 1-20 [PMID: 31966910 DOI: 10.4251/wjgo.v12.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
84 Wang HW, Yan XL, Wang LJ, Zhang MH, Yang CH, Wei-Liu, Jin KM, Bao Q, Li J, Wang K, Xing BC. Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases. J Transl Med 2021;19:313. [PMID: 34281583 DOI: 10.1186/s12967-021-02986-0] [Reference Citation Analysis]
85 Vaňková B, Vaněček T, Ptáková N, Hájková V, Dušek M, Michal M, Švajdler P, Daum O, Daumová M, Michal M, Mezencev R, Švajdler M. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions. Genes Chromosomes Cancer 2020;59:562-8. [PMID: 32427409 DOI: 10.1002/gcc.22861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Auvray M, Baylot C, Blanc-Durand F, Borcoman E, Pons-Tostivint E, Vignot S. [Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations]. Bull Cancer 2018;105:1084-93. [PMID: 30340752 DOI: 10.1016/j.bulcan.2018.08.010] [Reference Citation Analysis]
87 Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N. Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers (Basel) 2019;11:E859. [PMID: 31226844 DOI: 10.3390/cancers11060859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
88 Stenzinger A, van Tilburg CM, Tabatabai G, Länger F, Graf N, Griesinger F, Heukamp LC, Hummel M, Klingebiel T, Hettmer S, Vokuhl C, Merkelbach-Bruse S, Overkamp F, Reichardt P, Scheer M, Weichert W, Westphalen CB, Bokemeyer C, Ivanyi P, Loges S, Schirmacher P, Wörmann B, Bielack S, Seufferlein TTW. [Diagnosis and therapy of tumors with NTRK gene fusion]. Pathologe 2021;42:103-15. [PMID: 33258061 DOI: 10.1007/s00292-020-00864-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Chen C, Di Bartolomeo M, Corallo S, Strickler JH, Goyal L. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. Am Soc Clin Oncol Educ Book 2020;40:161-73. [PMID: 32421451 DOI: 10.1200/EDBK_280871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
90 Ruiz-Bañobre J, Goel A. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Adv Cancer Res 2021;151:231-304. [PMID: 34148615 DOI: 10.1016/bs.acr.2021.02.008] [Reference Citation Analysis]
91 Parikh DA, Walia G, Freeman-Daily J, Hennink M, Tomalia T, Buonanno L, Goldman L, Addario B, Patel MI. Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository. JCO Oncol Pract 2020;16:e183-9. [PMID: 31880972 DOI: 10.1200/JOP.19.00135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
92 Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F. Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open 2019;4:e000489. [PMID: 30962964 DOI: 10.1136/esmoopen-2019-000489] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
93 Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Exploration of Targeted Anti-tumor Therapy 2020;1:53-70. [DOI: 10.37349/etat.2020.00004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2018;2018. [PMID: 30637364 DOI: 10.1200/PO.18.00183] [Cited by in Crossref: 77] [Cited by in F6Publishing: 47] [Article Influence: 19.3] [Reference Citation Analysis]
95 DeStefanis RA, Kratz JD, Emmerich PB, Deming DA. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep 2019;15:61-9. [PMID: 31130830 DOI: 10.1007/s11888-019-00430-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
96 Lasota J, Chłopek M, Lamoureux J, Christiansen J, Kowalik A, Wasąg B, Felisiak-Gołąbek A, Agaimy A, Biernat W, Canzonieri V, Centonze G, Chmielik E, Daum O, Dubová M, Dziuba I, Goertz S, Góźdź S, Guttmejer-Nasierowska A, Haglund C, Hałoń A, Hartmann A, Inaguma S, Iżycka-Świeszewska E, Kaczorowski M, Kita P, Kołos M, Kopczyński J, Michal M, Milione M, Okoń K, Pęksa R, Pyzlak M, Ristimäki A, Ryś J, Szostak B, Szpor J, Szumiło J, Teresiński L, Waloszczyk P, Wejman J, Wesołowski W, Miettinen M. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature. Am J Surg Pathol 2020;44:162-73. [PMID: 31567189 DOI: 10.1097/PAS.0000000000001377] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
97 Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol 2021;28:523-48. [PMID: 33467570 DOI: 10.3390/curroncol28010053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Corti G, Bartolini A, Crisafulli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Barault L, Siravegna G, Siena S, Marsoni S, Di Nicolantonio F, Medico E, Bardelli A. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Clinical Colorectal Cancer 2019;18:91-101.e3. [DOI: 10.1016/j.clcc.2019.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
99 Santos C, Sanz-pamplona R, Salazar R. RET-fusions: a novel paradigm in colorectal cancer. Annals of Oncology 2018;29:1340-3. [DOI: 10.1093/annonc/mdy132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
100 Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol 2019;30 Suppl 8:viii5-viii15. [PMID: 32223939 DOI: 10.1093/annonc/mdz383] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]